Motif Bio plc announced that new iclaprim data are being presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019) in Amsterdam, The Netherlands. Efficacy analysis by lesion size demonstrates iclaprim had comparable efficacy to vancomycin across broad range of lesion sizes in REVIVE Phase III study patients. Larger-size acute bacterial skin and skin structure infection (ABSSSI) lesions may be more difficult to treat. A post-hoc analysis by lesion size of the pooled data from the REVIVE-1 and REVIVE-2 Phase III trials evaluating iclaprim versus vancomycin for the treatment of ABSSSI patients showed that fixed dosing of iclaprim had similar efficacy results compared to weight/renal function-based dosing of vancomycin across a broad range of lesion sizes, including lesions 800 cm2 or greater. Clearance of bacteremia comparable in patients treated with iclaprim versus vancomycin in pooled analysis of REVIVE Phase III study results. Secondary bacteremia is a complication among patients with ABSSSI and is associated with increased morbidity and mortality. A post-hoc analysis evaluated bacteremia outcomes in patients in the REVIVE trials. There were 12/592 patients in the iclaprim arm and 12/606 patients in the vancomycin arm with secondary bacteremia. In each group, 83% of patients cleared their bacteremia by the test of cure visit (7 to 14 days after end of therapy).